Mark Cervi
Internal Medicine · Greenville, NCNPI 1700846672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 309 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,152 and has fallen 78.9% since, to $455 in 2022. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$655
- Amgen$628
- GSK$454
- AbbVie$417
- Lilly USA, LLC$284
- Novo Nordisk$249
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,066100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $655 |
| Amgen | 44 | $628 |
| GSK | 22 | $454 |
| AbbVie(2 entities) | 21 | $417 |
| Lilly USA, LLC | 20 | $284 |
| Novo Nordisk | 18 | $249 |
| Boehringer Ingelheim | 14 | $215 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $209 |
| Pfizer | 15 | $205 |
| Merck | 15 | $201 |
| Akcea Therapeutics, Inc. | 4 | $152 |
| Eisai Inc. | 8 | $117 |
| Boston Scientific | 6 | $115 |
| Regeneron Healthcare Solutions, Inc. | 6 | $113 |
| Esperion Therapeutics, Inc. | 7 | $111 |
| Novartis | 7 | $97 |
| Biohaven Pharmaceuticals, Inc. | 6 | $93 |
| Astellas Pharma US Inc | 5 | $81 |
| Kowa Pharmaceuticals America, Inc. | 6 | $75 |
| Grifols USA, LLC | 3 | $63 |
| Amarin Pharma, Inc. | 4 | $63 |
| Acerus Pharmaceuticals Corporation | 2 | $50 |
| Dynavax Technologies Corporation | 4 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Abbott | 2 | $39 |
| Gilead | 3 | $37 |
| Aytu Biopharma, Inc. | 2 | $36 |
| Clarus Therapeutics Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $28 |
| Phadia US Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$225
- TRELEGY ELLIPTA$124
- VRAYLAR$100
How this compares
$5,086 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Greenville
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.